Trial · NCT05642442
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score | Sulvecaltamide | -6.4 | Standard Deviation 5.39 | score on a scale | |
| Change From Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score | Placebo | -5.3 | Standard Deviation 5.73 | score on a scale | |
| Percentage of Participants Who Improved (≥ 1-point Improvement) From Baseline to Week 17 on the Clinical Global Impression of Severity (CGI-S) | Sulvecaltamide | 54.6 | percentage of participants | ||
| Percentage of Participants Who Improved (≥ 1-point Improvement) From Baseline to Week 17 on the Clinical Global Impression of Severity (CGI-S) | Placebo | 40.1 | percentage of participants | ||
| Change From Baseline to Week 17 on The Essential Tremor Rating Scale, Activities of Daily Living Subscale (TETRAS-ADL) | Sulvecaltamide | -7.5 | Standard Deviation 7.04 | score on scale | |
| Change From Baseline to Week 17 on The Essential Tremor Rating Scale, Activities of Daily Living Subscale (TETRAS-ADL) | Placebo | -5.8 | Standard Deviation 6.48 | score on scale | |
| Percentage of Participants Who Improved (≥ 1 Point) From Baseline to Week 17 on the Patient's Global Impression of Severity (PGI-S) | Sulvecaltamide | 54.0 | percentage of patients | ||
| Percentage of Participants Who Improved (≥ 1 Point) From Baseline to Week 17 on the Patient's Global Impression of Severity (PGI-S) | Placebo | 43.7 | percentage of patients | ||
| Percentage of Participants Who Were Much Improved on the Patient's Global Impression of Change (PGI-C) at Week 17 | Sulvecaltamide | 23.9 | percentage of patients | ||
| Percentage of Participants Who Were Much Improved on the Patient's Global Impression of Change (PGI-C) at Week 17 | Placebo | 8.2 | percentage of patients | ||
| Percentage of Participants Who Were Much Improved on the Clinician's Global Impression of Change (CGI-C) at Week 17 | Sulvecaltamide | 15.7 | percentage of patients | ||
| Percentage of Participants Who Were Much Improved on the Clinician's Global Impression of Change (CGI-C) at Week 17 | Placebo | 8.1 | percentage of patients | ||
| Change From Baseline to Week 17 on The Essential Tremor Rating Scale, Performance Subscale (TETRAS-PS) | Sulvecaltamide | -4.2 | Standard Deviation 5.41 | score on a scale | |
| Change From Baseline to Week 17 on The Essential Tremor Rating Scale, Performance Subscale (TETRAS-PS) | Placebo | -5.9 | Standard Deviation 6.37 | score on a scale | |
| Change From Baseline to Week 17 on TETRAS Total Score (TETRAS-ADL + TETRAS-PS) | Sulvecaltamide | -11.7 | Standard Deviation 10.15 | score on a scale | |
| Change From Baseline to Week 17 on TETRAS Total Score (TETRAS-ADL + TETRAS-PS) | Placebo | -11.7 | Standard Deviation 10.48 | score on a scale | |
| Change From Baseline to Week 17 on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Tremor Score | Sulvecaltamide | -3.5 | Standard Deviation 3.80 | score on a scale | |
| Change From Baseline to Week 17 on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Tremor Score | Placebo | -3.1 | Standard Deviation 5.08 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05642442/results